Van Berkom & Associates Inc. Sells 46,221 Shares of Charles River Laboratories International, Inc. $CRL

Key Points

• Van Berkom & Associates sold 46,221 shares of Charles River, cutting its stake by 9.3% to 450,690 shares, which represents about 2.6% of its portfolio and ~0.92% of CRL (~$89.9M).
• Charles River beat quarterly estimates with $2.39 EPS (vs. $2.33) and $994.2M revenue (vs. $987.0M), and set FY2026 guidance of 10.700–11.200 EPS versus analysts' 10.97 consensus.
• Wall Street sentiment is generally positive—consensus rating " Moderate Buy" with an average price target of $205.36—while shares trade around $172.10 and the company has an $8.49B market cap.

Van Berkom & Associates Inc. lessened its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 9.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 450,690 shares of the medical research company's stock after selling 46,221 shares during the period. Charles River Laboratories International accounts for about 2.6% of Van Berkom & Associates Inc.'s portfolio, making the stock its 11th biggest holding. Van Berkom & Associates Inc. owned about 0.92% of Charles River Laboratories International worth $89,904,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Tema Etfs LLC purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $26,000. Rothschild Investment LLC raised its position in Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company's stock valued at $29,000 after purchasing an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new position in shares of Charles River Laboratories International during the 3rd quarter worth approximately $31,000. Activest Wealth Management grew its stake in shares of Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company's stock worth $44,000 after buying an additional 218 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its position in Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company's stock valued at $44,000 after acquiring an additional 145 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Trading Up 3.8%

Shares of Charles River Laboratories International stock opened at $172.10 on Tuesday. The firm has a 50-day simple moving average of $169.78 and a two-hundred day simple moving average of $183.17. The company has a market cap of $8.49 billion, a P/E ratio of -58.14, a price-to-earnings-growth ratio of 2.01 and a beta of 1.44. Charles River Laboratories International, Inc. has a fifty-two week low of $113.89 and a fifty-two week high of $228.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping analysts' consensus estimates of $2.33 by $0.06. The business had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company's revenue was down .8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 10.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of research analyst reports. Barclays raised their price objective on Charles River Laboratories International from $200.00 to $210.00 and gave the company an "overweight" rating in a research report on Tuesday, April 14th. Mizuho decreased their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating for the company in a research note on Friday, February 20th. Evercore reaffirmed an "outperform" rating on shares of Charles River Laboratories International in a research note on Wednesday, April 8th. Citigroup lifted their price objective on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the company a "buy" rating in a report on Friday, January 16th. Finally, Royal Bank Of Canada began coverage on shares of Charles River Laboratories International in a report on Tuesday, April 14th. They issued an "outperform" rating and a $215.00 price target on the stock. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $205.36.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.